Australia markets closed

Recursion Pharmaceuticals, Inc. (RXRX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.84+0.05 (+0.57%)
At close: 04:00PM EDT
8.88 +0.04 (+0.45%)
After hours: 07:57PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.10B
Enterprise value 1.76B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)41.88
Price/book (mrq)4.53
Enterprise value/revenue 40.09
Enterprise value/EBITDA -5.72

Trading information

Stock price history

Beta (5Y monthly) 0.75
52-week change 356.96%
S&P500 52-week change 322.38%
52-week high 316.75
52-week low 34.92
50-day moving average 310.07
200-day moving average 39.25

Share statistics

Avg vol (3-month) 36.39M
Avg vol (10-day) 34.66M
Shares outstanding 5230.11M
Implied shares outstanding 6237.52M
Float 8189M
% held by insiders 15.57%
% held by institutions 192.80%
Shares short (15 Apr 2024) 438.7M
Short ratio (15 Apr 2024) 47.16
Short % of float (15 Apr 2024) 424.58%
Short % of shares outstanding (15 Apr 2024) 416.30%
Shares short (prior month 15 Mar 2024) 443.52M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-919.27%

Management effectiveness

Return on assets (ttm)-32.29%
Return on equity (ttm)-69.12%

Income statement

Revenue (ttm)44.58M
Revenue per share (ttm)0.21
Quarterly revenue growth (yoy)-20.40%
Gross profit (ttm)N/A
EBITDA -325.66M
Net income avi to common (ttm)-328.07M
Diluted EPS (ttm)-1.58
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)391.56M
Total cash per share (mrq)1.67
Total debt (mrq)50.67M
Total debt/equity (mrq)10.93%
Current ratio (mrq)4.70
Book value per share (mrq)1.98

Cash flow statement

Operating cash flow (ttm)-287.78M
Levered free cash flow (ttm)-187.37M